Hot Life Science Investor Mandate 3: European Evergreen Investment Firm Looking Globally for Revolutionary Life Science Opportunities

13 Nov

A European Evergreen Investment Firm is mandated to invest in companies with the potential to make major breakthroughs in healthcare. The investment size will usually range from £1M – £20M per company. The firm seeks to create sustainable, profitable businesses, to support them with capital over the long term, for the benefit of patients. The firm is actively screening new investment opportunities and is open to reviewing opportunities from around the globe.

The firm seeks to invest in early-late stage biotech therapeutics, diagnostics, medical devices, and healthcare IT. Currently, the firm is highly interested in Gene and Cell therapies and patient stratification. Technologies/products that target orphan diseases or small patient populations are also of interest. The firm only selects truly revolutionary technologies and has no interest in incremental improvements to efficacy/safety.

The firm seeks to be a long term investor and does not look to exit or IPO their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: